WO2023285842A1 - Method of determining the identity of a biomolecule - Google Patents
Method of determining the identity of a biomolecule Download PDFInfo
- Publication number
- WO2023285842A1 WO2023285842A1 PCT/GB2022/051853 GB2022051853W WO2023285842A1 WO 2023285842 A1 WO2023285842 A1 WO 2023285842A1 GB 2022051853 W GB2022051853 W GB 2022051853W WO 2023285842 A1 WO2023285842 A1 WO 2023285842A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biomolecule
- sample
- mobility
- measurements
- mass
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 122
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 238000000149 argon plasma sintering Methods 0.000 claims abstract description 17
- 238000005259 measurement Methods 0.000 claims description 83
- 230000003993 interaction Effects 0.000 claims description 53
- 239000002245 particle Substances 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 239000011521 glass Substances 0.000 claims description 21
- 150000002632 lipids Chemical class 0.000 claims description 19
- -1 polyethylene Polymers 0.000 claims description 19
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims description 15
- 239000004698 Polyethylene Substances 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 230000004048 modification Effects 0.000 claims description 13
- 238000012986 modification Methods 0.000 claims description 13
- 229920000573 polyethylene Polymers 0.000 claims description 13
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 claims description 12
- 230000033001 locomotion Effects 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 claims description 9
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 102000001708 Protein Isoforms Human genes 0.000 claims description 8
- 108010029485 Protein Isoforms Proteins 0.000 claims description 8
- 239000004743 Polypropylene Substances 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 7
- 230000003196 chaotropic effect Effects 0.000 claims description 7
- 239000003599 detergent Substances 0.000 claims description 7
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 7
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 7
- 229920001155 polypropylene Polymers 0.000 claims description 7
- 150000004756 silanes Chemical class 0.000 claims description 7
- 239000005051 trimethylchlorosilane Substances 0.000 claims description 7
- 239000000232 Lipid Bilayer Substances 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 239000003638 chemical reducing agent Substances 0.000 claims description 6
- 239000003431 cross linking reagent Substances 0.000 claims description 6
- 229920001903 high density polyethylene Polymers 0.000 claims description 6
- 229920005669 high impact polystyrene Polymers 0.000 claims description 6
- 239000004700 high-density polyethylene Substances 0.000 claims description 6
- 239000004797 high-impact polystyrene Substances 0.000 claims description 6
- 229920001684 low density polyethylene Polymers 0.000 claims description 6
- 239000004702 low-density polyethylene Substances 0.000 claims description 6
- 239000004417 polycarbonate Substances 0.000 claims description 6
- 229920000515 polycarbonate Polymers 0.000 claims description 6
- 238000012429 release testing Methods 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 229920003023 plastic Polymers 0.000 claims description 5
- 239000004033 plastic Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 229920001342 Bakelite® Polymers 0.000 claims description 3
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims description 3
- 239000004713 Cyclic olefin copolymer Substances 0.000 claims description 3
- 239000004593 Epoxy Substances 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 229920007019 PC/ABS Polymers 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 239000012317 TBTU Substances 0.000 claims description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004637 bakelite Substances 0.000 claims description 3
- 150000007942 carboxylates Chemical class 0.000 claims description 3
- 239000010432 diamond Substances 0.000 claims description 3
- 229910003460 diamond Inorganic materials 0.000 claims description 3
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004816 latex Substances 0.000 claims description 3
- 229920000126 latex Polymers 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 229920000962 poly(amidoamine) Polymers 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 3
- 239000005033 polyvinylidene chloride Substances 0.000 claims description 3
- 239000005060 rubber Substances 0.000 claims description 3
- 239000010980 sapphire Substances 0.000 claims description 3
- 229910052594 sapphire Inorganic materials 0.000 claims description 3
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 claims description 3
- ACECBHHKGNTVPB-UHFFFAOYSA-N silylformic acid Chemical class OC([SiH3])=O ACECBHHKGNTVPB-UHFFFAOYSA-N 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 239000002479 lipoplex Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 7
- 239000000356 contaminant Substances 0.000 abstract description 5
- 230000007613 environmental effect Effects 0.000 abstract description 5
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 136
- 230000037230 mobility Effects 0.000 description 63
- 229940027941 immunoglobulin g Drugs 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 241000702421 Dependoparvovirus Species 0.000 description 17
- 230000003287 optical effect Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 13
- 238000005286 illumination Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000090 biomarker Substances 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 8
- 150000005829 chemical entities Chemical class 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000000386 microscopy Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 238000005375 photometry Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000004075 alteration Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001427 coherent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000012023 real time release testing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 229910000077 silane Inorganic materials 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000010399 physical interaction Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000002310 reflectometry Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical class COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 238000000533 capillary isoelectric focusing Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035071 co-translational protein modification Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000001446 dark-field microscopy Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000005099 host tropism Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 239000002107 nanodisc Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/02—Investigating particle size or size distribution
- G01N15/0205—Investigating particle size or size distribution by optical means
- G01N15/0227—Investigating particle size or size distribution by optical means using imaging; using holography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
- G01N15/1433—Signal processing using image recognition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1434—Optical arrangements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/41—Refractivity; Phase-affecting properties, e.g. optical path length
- G01N21/45—Refractivity; Phase-affecting properties, e.g. optical path length using interferometric methods; using Schlieren methods
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03H—HOLOGRAPHIC PROCESSES OR APPARATUS
- G03H1/00—Holographic processes or apparatus using light, infrared or ultraviolet waves for obtaining holograms or for obtaining an image from them; Details peculiar thereto
- G03H1/04—Processes or apparatus for producing holograms
- G03H1/0443—Digital holography, i.e. recording holograms with digital recording means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1021—Measuring mass of individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1027—Determining speed or velocity of a particle
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1434—Optical arrangements
- G01N2015/1454—Optical arrangements using phase shift or interference, e.g. for improving contrast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1493—Particle size
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03H—HOLOGRAPHIC PROCESSES OR APPARATUS
- G03H1/00—Holographic processes or apparatus using light, infrared or ultraviolet waves for obtaining holograms or for obtaining an image from them; Details peculiar thereto
- G03H1/32—Systems for obtaining speckle elimination
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03H—HOLOGRAPHIC PROCESSES OR APPARATUS
- G03H1/00—Holographic processes or apparatus using light, infrared or ultraviolet waves for obtaining holograms or for obtaining an image from them; Details peculiar thereto
- G03H1/0005—Adaptation of holography to specific applications
- G03H2001/005—Adaptation of holography to specific applications in microscopy, e.g. digital holographic microscope [DHM]
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03H—HOLOGRAPHIC PROCESSES OR APPARATUS
- G03H1/00—Holographic processes or apparatus using light, infrared or ultraviolet waves for obtaining holograms or for obtaining an image from them; Details peculiar thereto
- G03H1/04—Processes or apparatus for producing holograms
- G03H1/0402—Recording geometries or arrangements
- G03H2001/0428—Image holography, i.e. an image of the object or holobject is recorded
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03H—HOLOGRAPHIC PROCESSES OR APPARATUS
- G03H2210/00—Object characteristics
- G03H2210/62—Moving object
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03H—HOLOGRAPHIC PROCESSES OR APPARATUS
- G03H2222/00—Light sources or light beam properties
- G03H2222/40—Particular irradiation beam not otherwise provided for
- G03H2222/43—Object beam at recording stage
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03H—HOLOGRAPHIC PROCESSES OR APPARATUS
- G03H2223/00—Optical components
- G03H2223/12—Amplitude mask, e.g. diaphragm, Louver filter
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03H—HOLOGRAPHIC PROCESSES OR APPARATUS
- G03H2223/00—Optical components
- G03H2223/50—Particular location or purpose of optical element
- G03H2223/52—Filtering the object information
Definitions
- the present invention relates to an improved method for determining the identity of a biomolecule, notably distinguishing between variants of biomolecules, such as viral serotypes and the like. Such a method has potential to simplify the testing for biological manufacture and for diagnosing disease, monitoring environmental issues and determination of contaminants.
- a biological medicine, or biologic may be described as a treatment containing complex active substances made by a biological process or derived from a biological source.
- "Biologies" is a broad term and encompasses a wide range of products such as cells, tissues, blood derived products, nucleic acids, recombinant proteins, antibodies, vaccines, gene therapy viruses, hormones, and enzymes. Biologic drugs are generally administered by injection or infusion and are already available to treat numerous diseases.
- Biologicales includes the use of living cells such as human cells, animal cells or microorganisms, generally using genetic manipulation methods.
- monoclonal antibodies may be produced in Chinese hamster ovary cells (CHO).
- Biologies testing is a critical process during production, as these complex molecules may be altered by changes in their manufacturing processes; they may have sensitivity to factors that could cause aggregation and degradation which impacts biologic activity, product safety, and quality. Unintended or unexplained alterations in manufacturing processes can lead to differing product attributes (i.e., drift). Determining the exact nature of the product is therefore critical.
- Quality, safety, and efficacy must be continually monitored and in order to meet strict regulatory requirements. For example, determining the presence, identity and concentration of contaminants during production is a regulatory requirement.
- MAbs monoclonal antibodies
- Recent advances in molecular biology, immunology, and development of robust production platforms will drive the development of more antibodies suitable to treat other diseases and conditions. It is expected that this will lead to development of larger industrial facilities to increase production to meet increasing demand.
- Those in this area are aware of the critical quality control attributes particular to antibodies, and scale-up considerations that need to be made. (Gaughan, C.L., Molecular Diversity volume 20, pages 255- 270 (2016)).
- drift and release or finished product testing may involve numerous testing protocols, including but not limited to: appearance, osmolality, pH, cell-based bioassays, endotoxin testing, various chromatography techniques: size exclusion chromatography; reversed-phase chromatography; ion-exchange chromatography, amino acid analysis, protein concentration determination, peptide mapping, glycan profiling, capillary gel electrophoresis, capillary isoelectric focussing, and host cell assays including sugar, vitamin, metabolite, protein (generally ELISA) and DNA determination.
- chromatography techniques size exclusion chromatography; reversed-phase chromatography; ion-exchange chromatography, amino acid analysis, protein concentration determination, peptide mapping, glycan profiling, capillary gel electrophoresis, capillary isoelectric focussing, and host cell assays including sugar, vitamin, metabolite, protein (generally ELISA) and DNA determination.
- Real-time release testing is defined as "the ability to evaluate and ensure the quality of in-process and/or final drug product based on process data, which typically includes a valid combination of measured material attributes and process controls" (Jiang et al., Biotech & Bioeng 2017, hltps://doi.org/lQ,lQ02/bit.26383).
- RTRT Real-time release testing
- manufacturers are looking at the practicalities of implementing this approach, and therefore, is not yet fully benefitting from its promises. Many problems remain, including which instrumentation to use and when and where during manufacturing to perform assays.
- Mass photometry provides an efficient and effective method to measure the mass and relative concentration of biomolecules in a sample. This technique measures the mass of individual biomolecules by capturing the light scattered by each molecule at an interface. Extraction of the scattering contrast provides an indirect measurement of the mass. Mass photometry builds on the principles of interference reflection microscopy and interferometric scattering microscopy.
- the biomolecules of similar mass may be related to each other, i.e. isoforms of the same biomolecule.
- the biomolecules of similar mass may be variants of the same biomolecule.
- Such determination would enable techniques such as release testing to be performed, wherein the sample is known to comprise a biomolecule.
- the method may be used to determine a particular characteristic of a molecule with a certain mass. In release testing, the predicted mass of the biomolecule may be known, and therefore determination of further characteristics of molecules with an appropriate mass may be determined.
- Biomolecules play indispensable roles in biological processes, including disease development, so the accurate detection and/or identification of biomolecules is critical to disease diagnosis and therapy. Further, given that biological environmental and industrial samples and the like may also contain particles of a similar mass, a method to identify a biomolecule in a sample may have further applications.
- Bio molecules are undoubtedly complex. Biological molecules produced in cells are processed according to the cellular pathways of the cell. Different processing even in a natural setting can result in the production of isoforms. Host cells may use different pathways for processing when compared to the originating cell for the biological molecule. This may results in differential processing, for example, changes in protein folding, changes in nucleic acid methylation, changes in glycosylation patterns, changes in surface charge and the like. The physical characteristics of the biological molecule can therefore be altered by processing in a different cell type. Biological molecules may be classified into four general classes, proteins, carbohydrates, lipids and nucleic acids, depending on the monomer unit employed.
- Biomolecules may be composed of more than one kind of monomer, for example glycosylated proteins, glycosylated RNA, lipoproteins, lipid-modified oligonucleotides and glycolipids.
- biomolecules are folded to some degree, placing some of the monomers in the core, and exposing other monomers at the surface.
- Biological molecules therefore have a multitude of chemical groups on their surface, all of which help to determine the physical characteristics of the biomolecule. Changes to the way the biological molecule is produced is likely to alter the surface chemistry, leading to a change in the characteristics, particularly of the surface. Similarly, if the molecule changes conformation and previously internal sections form part of the exterior surface, these will have particular characteristics too.
- Biomolecules whether protein, carbohydrate, or nucleic acid, can be distinguished from other molecules based on differences in some physical characteristics. Physical characteristics include, but are not limited to size, defined as either length or mass, charge, binding affinities (such as the ability to form weak, noncovalent bonds i.e. hydrogen bonds, ionic bonds, and van der Waals attractions; plus favourable hydrophobic interactions) and hydrophobicity. Biomolecules therefore may be defined by their molecular weight (mass) and by their isoelectric point (pi), for example.
- the isoelectric or isoionic point of a biomolecule is the pH at which the biomolecule carries no net electrical charge and hence considered neutral.
- the pi of biomolecules is mainly dependent on the dissociation constant (Kd) of any ionisable groups.
- Kd dissociation constant
- Arginine, aspartate, cysteine, histidine, glutamate, lysine, and glutamate are all exemplary ionisable groups in proteins and they play a major role in determining the pi of a protein.
- co-translational and post-translational modifications can have a significant role in determining the pi of a biomolecule.
- All biomolecules including without limitation, viruses, nucleic acids, polysaccharides and lipids, will have an isoelectric point.
- the present invention relies upon the interaction of a biomolecule with a surface. How a biomolecule interacts with a surface is determined by the properties or characteristics of that biomolecule. This can be exploited by selecting an appropriate surface to determine a particular property or characteristic, with or without altering one or more condition in which the biomolecule is contacted with the surface, for example temperature.
- the interaction of the biomolecule and the surface may be determined using interferometric light scattering microscopy. Such a technique interrogates the interface of the surface and the sample, and detects biomolecules that interact with the surface. Each biomolecule may be tracked by taking repeated measurements, giving a picture of the interaction of the biomolecule and the surface. This permits a determination of the mobility of the biomolecule on the surface.
- the interaction between the surface and the biomolecule may be due to any kind of interaction, from hydrophobicity to covalent bond formation.
- the interaction between the surface and the biomolecule may be due to ionic/ electrostatic interactions. These interactions are due to the physical characteristics of the biomolecule.
- the present invention thus provides a method of determining the identity of a biomolecule in a sample comprising determining the interaction of a biomolecule with a surface.
- a method of identifying a biomolecule in a sample using an interferometric light scattering apparatus comprising:
- step (ii) repeating step (i) using a second surface and determining the mobility of said biomolecule on said surface;
- step (iii) using the mobility of the biomolecule determined in step (i) and step (ii) to construct a profile for said biomolecule
- step (iv) comparing the profile obtained in step (iii) with at least one reference profile to identify the biomolecule.
- the method of the present invention therefore comprises several steps which may be performed in any appropriate order.
- a surface may be selected such that the surface chemistry permits determination of at least one physical characteristic of the biomolecule.
- the surface may be selected to determine the interaction of the biomolecule with the surface, most notably the mobility of the biomolecule on the surface.
- the surface is contacted with the sample, which may contain the biomolecule.
- the condition or conditions under which the surface is contacted with the sample may be selected to permit determination of at least one physical characteristic of the biomolecule.
- the surface may be selected to determine the interaction of the biomolecule with the surface, most notably the mobility of the biomolecule on the surface.
- the identity of a biomolecule in a sample may be determined by determining the mobility of the biomolecule on the surface by creating or preparing a profile, which profile includes the data obtained from at least a first surface and a second surface (for example steps (i) and (ii)).
- the first and second surface may be different surfaces.
- the first and second surfaces may be the same surface.
- the second surface is contacted with the sample under at least one altered condition (when compared to the first surface).
- An altered condition may be selected from any one of: temperature; pH; ionic strength, redox potential, electric potential applied between surface and solution and presence of a reagent.
- a reagent may be any reagent that alters the interaction of the biomolecule and the surface, such as any one or more of: detergent, chaotropic agent, reducing agent, buffer, ion, salt, solvent, denaturing agent, and/or cross-linking agent. A plurality of conditions may be altered as required.
- repeated measurements may be taken of that biomolecule whilst it remains in contact with the surface. This enables tracking of the biomolecule as it moves across the surface, as appropriate.
- These repeated measurements are described as taking a "plurality of measurements” and may also be described as measurements taken over time or a period of time.
- the rate at which these measurements are taken may be selected appropriately depending on the expected mobility of the biomolecule.
- the rate may be in the range of 10Hz to 10kHz, optionally 50Hz to 5KHz, preferably 100Hz to 1kHz. Any suitable rate may be selected within or from these ranges.
- the plurality of measurements are thus taken of the biomolecule over time to monitor the mobility of the molecule on the surface.
- Taking a plurality of measurements of the interaction of the biomolecule with the surface permits tracking of that biomolecule. Detection and/or tracking can be performed at the level of a single biomolecule.
- any measurement may be used to determine the mass of the biomolecule, optionally a measurement taken in step (i) or step (ii) may be used, or an independent measurement may be taken to determine mass.
- a reference profile may be prepared by taking a known biomolecule and performing the method with at least a first and second surface. This reference profile may be single combined profile or a set of profiles obtained from each surface. A summary of the interactions (such as the mobility) of a biomolecule with a surface may be used to construct a profile.
- a profile may be defined as a set of characteristics that identify or are thought to identify a particular biomarker.
- the profile may be a summary or analysis of data, in any appropriate form, such as a graph or table, representing distinctive characteristics.
- a method of identifying a biomolecule in a sample comprising contacting said sample with a first surface and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the first surface to determine at least one physical characteristic of said biomolecule.
- the first surface may be selected such that the surface chemistry permits determination of at least one physical characteristic of the biomolecule.
- the first surface is contacted with the sample, which may contain the biomolecule.
- the conditions under which the first surface is contacted with the sample may be selected to permit determination of at least one physical characteristic of the biomolecule.
- the identity of a biomolecule in a sample may be determined by determining mass and mobility of the biomolecule on the first surface without further measurements being required. Alternatively, further measurements may be required, for example in more complex samples or where potential variants of the biomolecule have similar characteristics.
- Further measurements may comprise: contacting said sample with a second surface and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the second surface to determine at least one physical characteristic of said biomolecule.
- further measurements may comprise: contacting said sample with a first surface and altering one or more conditions of said sample to determine at least one physical characteristic of said biomolecule.
- Said conditions may be defined as the conditions that affect the binding of the biomolecule to the surface, thus affecting the reaction of the surface and the biomolecule.
- the conditions of the sample include, but are not limited to: temperature, pH, ionic strength, presence of chemical entities such as detergents, chaotropic agents, reducing agents, oxidising agents, redox reagents, buffers, ions, solvent, denaturing agent, and/or cross-linking agents.
- chemical entities such as detergents, chaotropic agents, reducing agents, oxidising agents, redox reagents, buffers, ions, solvent, denaturing agent, and/or cross-linking agents.
- the measurements obtained with the different surface and/or altered conditions can be combined with or compared to the measurements obtained with the first surface to provide sufficient information to identify the biomolecule. This may result in the determination of the mass of the biomolecule and two or more physical characteristics.
- a profile consistent with a biomolecule may be determined. This profile may be sufficient alone to determine the identity of a biomolecule, or the profile may be compared to a reference profile previously obtained for a known biomolecule.
- the present method provides a method of identifying a biomolecule in a sample, said method comprising: contacting said sample with a first surface, and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the first surface, and using said mass and mobility to define a profile for the biomolecule which may be compared to a reference profile.
- the method may be repeated with a second surface and/or with a second set of conditions in order to supplement the profile.
- the method may be repeated with a further surface and/or with a further set of conditions to supplement the profile.
- the present method provides a method of identifying a biomolecule in a sample, said method comprising: contacting said sample with a first surface, and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the first surface, contacting said sample with a second surface, and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the second surface, and combining or comparing the measurements on the first and second surfaces to determine the identity of the biomolecule.
- the present method provides a method of identifying a biomolecule in a sample, said method comprising: contacting said sample with a first surface under a first set of conditions, and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the first surface under the first conditions, contacting said sample with a first surface under a second set of conditions, and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the first surface under the second conditions, and combining or comparing the measurements under the first and second conditions to determine the identity of the biomolecule.
- the plurality of measurements over time may be used to determine the time of interaction of each biomolecule with the surface and/or the movements of a biomolecule over the surface.
- Such measurements may be considered to be the "mobility" of the biomolecule on the surface.
- the mobility may be defined as the distance travelled on the surface and/or the length of time the biomolecule interacts with the surface. Either or both may be measured. It is possible to measure the distance travelled by the biomolecule on the surface, it may be described as lateral or horizontal motion across the surface. Alternatively or additionally, the time of the interaction of the biomolecule with the surface may be measured. Such interaction time indicates motion from the surface, such that the biomolecule is no longer interacting with the surface but moves or diffuses into the sample solution. This form of mobility depends on the strength of the interaction of the biomolecule with the surface. The interaction between the surface and the biomolecule may be indicative of the characteristics of the biomolecule, thus providing information on the same.
- Fig. 1 is a schematic diagram of an interferometric light scattering (iSCAT) microscope
- Fig. 2 is an image captured by the iSCAT microscope
- Figure 3 depicts the distances moved by AAV5 and AAV9 in a sample, with the inset box showing the trajectories of motion of the virus particles on the surface;
- Figure 4A depicts the distances moved by IgG molecules on glass; whilst Figure 4B depicts the distances moved by IgG molecules on trimethylchlorosilane modified surface. The decreased movement on the trimethylchlorosilane modified surface is depicted; and
- Figure 5 is a depiction of a typical antibody molecule with possible groups available for interaction with the surface highlighted.
- biomolecules biological molecules
- biologies have surfaces with exposed chemical entities
- exemplary entities will include amino acid side chains in proteins, nucleotide bases in single stranded nucleic acids, sugar-phosphate backbone in nucleic acids, the chemistry and arrangement of the monosaccharide units in glycosylated biomolecules, hydrophobic side chains and polar head groups of some lipids, and any interacting metal ions or solvents with any of such groups.
- biomolecule may be described as an object, particle or species.
- the present invention involves contacting a biomolecule with a surface.
- the biomolecule may interact with this surface, and it is this interaction that the present invention seeks to determine, based on the mobility of the biomolecule (on/off and/or lateral mobility).
- the particle is tracked and imaged over time, such that the time of the interaction of the particle with the surface can be determined and/or the distance moved along the surface.
- Such parameters are indicative of the strength of the interaction between the biomolecule and the surface, which is an indirect determination of the physical characteristics of the biomolecule.
- the physical characteristics are generally the characteristics of the external surface of the biomolecule, but the sample may be placed under conditions where internal portions of the biomolecule are exposed (denatured or unfolded).
- the surface may be selected to interact with particular chemical entities.
- the material from which the surface is composed may be selected on the basis of its ability to interact with the chemical entities present on or in the biomolecule.
- the surface may be glass, and it is known that many biomolecules have a propensity to bind non-specifically to glass (for example, via protein adsorption).
- Figure 4A depicts the mobility of IgG on a glass surface, for example.
- Proteins and lipids may be described amphiphilic macromolecules since they possess both hydrophobic and hydrophilic groups attracted to nonpolar and polar groups, respectively. Hydrophilic and charged groups tend to be located on the exterior surface of a particle. However, hydrophobic groups also exist on external surfaces too. Such groups may interact electrostatically with surfaces. Binding of the particle occurs when the free energy between the particle and the surface is less than that of the surface and water (or other solvent).
- a surface for use in the present invention may be any suitable surface which is compatible with the interferometric detection method.
- a suitable surface may be capable of being functionalised or derivatised, or otherwise coated to alter the surface chemistry.
- a surface is suitably solid (i.e. not a gel or a liquid).
- the surface allows transmission of ultraviolet light (which may be defined herein as having wavelengths in the range from lOnm to 380nm); visible light (which may be defined herein as having wavelengths in the range from 380nm to 740nm); and/or infrared light (which may be defined herein as having wavelengths in the range from 740nm to 300pm).
- a surface allows transmission of light in the visible light spectrum.
- a surface is substantially transparent.
- a surface may be smooth or may be textured.
- a smooth surface is preferred.
- the surface may be patterned.
- a surface may be of any suitable material, including for example but without limitation glass, diamond, plastic, polymeric material (e.g. cyclic olefin copolymer, polyvinyl, polyethylene (PE) including for example polyethylene terephthalate (PET) and high-density polyethylene (HDPE) and low-density polyethylene (LDPE), polyacrylate (acrylic), polystyrene (PS) including high impact polystyrene (HIPS), silicone, polyester (for example polylactic acid (PLA) or polylactic coglycolic acid (PGLA)), polyurethane, polypropylene (PP), polyamide (nylon), Acrylonitrile butadiene styrene (ABS), Polyethylene/Acrylonitrile Butadiene Styrene (PE/ABS), bakelite, rubber, latex, polycarbonate (PC), Polycarbonate/Acrylonitrile Butadiene Styrene (PC/ABS) and polyvinyl chloride including for example
- a surface may include a lipid membrane, such as a lipid bilayer, lipid micelles, lipid nanodiscs and the like.
- the lipid bilayer may be any suitable bilayer, such as a supported lipid bilayer.
- the bilayer may be supported on a glass coverslip, for example.
- Such supported lipid bilayers as a surface for iSCAT are discussed in: Foley, E.D.B., et al. Mass photometry enables label-free tracking and mass measurement of single proteins on lipid bilayers. Nat Methods 18, 1247-1252 (2021) and Vala, M., Piliarik, M. Weighing single protein complexes on the go. Nat Methods 18, 1159-1160 (2021).
- the lipid membrane may be provided in any appropriate format, with any suitable lipid and/or protein formulation as required.
- the lipid membrane may have any suitable geometry.
- a surface may have any suitable geometry.
- a surface may comprise a flat plate, such as a coverslip, or may be a well, plate, bead, channel, container, flow cell, flow chamber, microfluidic cell or chamber, or slide.
- a surface may be part of a larger geometry or device.
- a suitable surface may be a glass coverslip or a plastic coverslip, wherein the plastic is as described above in relation to the surface.
- a surface preferably forms part of a sample holder.
- Said sample holder may be an element of a light scattering microscope.
- the sample holder may be a high surface-to-volume chamber.
- a surface may be functionalised.
- a surface may be passivated, activated, coated, treated or derivatised.
- the surface may be a passivated surface. Passivation is the process of treating or coating a surface in order to enhance or reduce the chemical reactivity, thus increasing or decreasing the number of interaction events.
- suitable passivating agents examples of which include BSA, PVPA, DDS and/or PEG.
- the surface is not passivated.
- a surface may be activated, coated, treated and/or derivatised to alter the chemistry of the surface.
- Functionalisation of a surface enables the determination of a particular characteristic of the biomolecule.
- Functionalisation of a surface may be to permit various interactions, such as chemical interactions (e.g. covalent bonding) or physical interactions (e.g. adsorption).
- chemical interactions e.g. covalent bonding
- physical interactions e.g. adsorption
- thin surface alterations may be desirable. Altered surface layers that are too thick can change the light scattering properties of the surface. Alteration of only the outermost few molecular layers (3-10 nm) may be desirable. Any suitable surface coating may be applied, in order to change the chemistry of the surface.
- the surface may be altered to increase hydrophobicity or increase hydrophilicity.
- Suitable methods and coatings will be known and available to persons skilled in the art, including for example and without limitation, functionalised PEG, silanes, carboxy-silanes, amines, aminosilane, trimethylchlorosilane, aldehyde modification with amine modification reagents such as APTES, epoxy modification using for example GOPTS, carboxylate modification using for example EDC, NHS, HOBt, TBTU, PAMAM; diazo using for example NaN0 , and supramolecules for example calixarenes.
- functionalised PEG silanes, carboxy-silanes, amines, aminosilane, trimethylchlorosilane, aldehyde modification with amine modification reagents such as APTES, epoxy modification using for example GOPTS, carboxylate modification using for example EDC, NHS, HOBt, TBTU, PAMAM; diazo using for example NaN0 , and supramolecules for example calixarenes.
- changing the surface chemistry of the surface does not substantially affect the light transmission of the surface.
- a hydrophobic coating may result in partial unfolding of proteins to expose a hydrophobic "internal" area, such that the determination of characteristics is further than the assessment of the external surface of the biomolecule.
- different binding characteristics may be tested, for example the introduction of different surface charges by coating amino or carboxyl-groups. At neutral pH, the amino group is protonated and the carboxyl group is deprotonated.
- the biomolecule may interact with the surface in a number of different ways.
- the biomolecule may be absorbed onto the surface, which is favoured by hydrophobic interactions, and may therefore require a hydrophobic surface.
- the biomolecule may react chemically with the functional groups of the surface via free reactive groups such as amine or carboxyl groups. Such covalent bonds restrict movement/mobility, both laterally and on/off the surface.
- Hydrophobic, hydrogen, van der Waals, ionic and coordinate bonding types, along with electrostatic interactions may also occur between the biomolecule and the surface. These types of interaction may be particularly affected by the conditions, such that changes in temperature and pH may alter the interaction of the biomolecule with the surface.
- the sample is contacted with the surface (first, second and/or further) and this may occur inside any apparatus for detecting light scattering. However, the step may be performed before the surface is placed into the apparatus. If the sample is repeatedly tested using different surfaces and/or different conditions, it will be appreciated by those skilled in the art that it is preferred to use a fresh (previously unused) sample to contact each surface. Thus, the methods of the invention may be described as being performed on a portion or an aliquot of a sample, such that multiple portions or aliquots may be contacted with a plurality of surfaces in parallel.
- the biomolecule may be any suitable biological molecule, including but not limited to proteins, polypeptides, peptides, glycoproteins, glycosaminoglycans, glycosphingolipids, lipoproteins, nucleic acids, oligomers, oligonucleotides, glycosylated nucleic acids, complexes of lipids and nucleic acids, lipids, glycolipids, triglycerides, phospholipids, steroids, carbohydrates, oligosaccharides and polysaccharides.
- the biomolecule can be an oligomer of various units, and form a larger structure, for example a virus particle.
- a virus may be identified in precisely the same way as a less complex biomolecule, by assessing characteristics including mass and/or mobility on a surface.
- the external parts of a virion may be proteinaceous or involve a lipid membrane.
- the biomolecule may therefore be a virus or a virus-like particle (VLP).
- the biomolecule may be a lipoplex, a lipid shell or a lipid nanoparticle (LNP), such as an LNP designed to deliver pharmaceuticals, such as RNA therapeutics.
- Biomolecules may be present in variant forms, for example isoforms, glycoforms, lipoforms, species, serotypes or mutants. It is an aim of several aspects of the invention to determine which variant biomolecule is present in the sample. For example, the methods of the present invention have been shown to be able to distinguish between virions of serotype AAV5 and AAV9, due to their differential movement across a surface. A profile based on this mobility could be used to distinguish between these AAV serotypes in an unknown sample.
- Isoforms may be encoded by the same gene, but involve differential processing. The resulting biomolecule may have a similar function and a similar mass but different characteristics.
- a serotype or serovar is a distinct variation within a species of virus.
- a glycoform is an isoform of a biomolecule that differs only with respect to the number or type of attached glycan. Glycoproteins often consist of a number of different glycoforms, with alterations in the attached saccharide or oligosaccharide. Variations in glycosylation is particularly pertinent with immunoglobulins. Different isoforms of lipids may exist, termed lipoforms.
- variants of a biomolecule generally have a similar mass, simply determining the mass may not provide sufficient information to more precisely determine the identity of the biomolecule.
- the present invention seeks to determine more information about the characteristics of the biomolecule, for example to determine charge, pi, or presence of particular chemical groups, such that the variant may be more closely identified. These could be described as the structural and physio-chemical characteristics of the biomolecule. For example, in the case of monoclonal antibodies important characteristics include mass, N/C-terminal, charge, glycosylation pattern, aggregation and FcgR binding.
- the predicted mass of the product may be known, but the present method seeks to provide further information about the product with a certain mass. This method enables the determination of further characteristics of a biomolecule beyond a determination of mass. Such is particularly important where the process could result in the incorrect glycosylation of a protein product.
- Proteins are composed of amino acid monomers, and these provide a diverse range of side chains which provide for many protein characteristics.
- Amino acid side chains vary in terms of size, charge, shape, hydrogen-bonding capacity, hydrophobic character, and chemical reactivity.
- the biomolecule is contacted with a surface, which may be prepared such that it provides different binding characteristics.
- the conditions can be altered to look for a specific effect.
- the conditions may be altered in any appropriate way, including but not limited to changing the pH, salt concentration, ionic strength, adding buffers, detergents, chaotropic agents and the like.
- changing the pH may change the net charge on the biomolecule (due to protonation/deprotonation) and this will have an impact on charge-mediated surface binding.
- Altering salt concentrations can also be used to influence charge-mediated binding. Changing the ionic strength permits denaturation of double stranded nucleic acids for example.
- Detergents, denaturants, chaotropic agents can be used to partial unfold or dissociate biomolecules in order to examine non surface-exposed characteristics.
- Cross-linking agents can stabilise molecules to permit closer examination of surface chemistries.
- the redox potential may be altered, for example by altering the concentration of oxidants and/or reductants in the sample.
- Another example of an altered condition is the application of an electric potential between the surface and the solution, which would alter the attraction of the biomolecule to the surface.
- the conditions of the sample include, but are not limited to: temperature, pH, ionic strength, presence of chemical entities/reagents such as detergents, chaotropic agents, reducing agents, buffers, ions, solvent, denaturing agent, and/or cross-linking agents. Further conditions include the redox potential and the application of an electric potential between the surface and the sample.
- the mass of the biomolecule may also be determined in the methods of the invention.
- the mass may be determined in any appropriate step, including any of steps (i) and/or (ii).
- An independent measurement step for determining the mass may be taken.
- Interferometric light scattering accurately measures molecular mass by quantifying light scattering from individual biomolecules in solution. Such techniques have previously been described, such as in Young and Kukura, Annual Review of Physical Chemistry 201970:1, 301-322; Young et at, Science 27 Apr 2018: Vol. 360, Issue 6387, pp. 423-427 and Strack, R. Weighing single proteins with light. Nat Methods 15, 477 (2018), all herein incorporated by reference.
- the sample may be any suitable sample, but is preferable taken from biomolecule manufacturing, such that a known biomolecule is present, and the method is used to determine whether the correct variant is present, and/or the presence of unwanted contaminants.
- the sample is therefore preferably not a complex sample with a plurality of different unknown biomolecules present, since the presence of many biomolecules of a similar mass may be confounding.
- the sample is preferably liquid, such as a solution or suspension.
- the sample may be a biological sample, such as a medical or veterinary sample.
- Such biological sample may be a bodily fluid of any appropriate type, or may be a suspension of a tissue of any appropriate type.
- the sample may be an environmental sample.
- Such environmental sample may be a water sample, or a sample taken from an environment and suspended in a solvent.
- the sample may be appropriately diluted prior to contacting the sample with a surface. Dilution may use any appropriate solvent, such as water. In Examples 1 and 2 the sample is appropriate diluted to ensure the number of biomolecule/surface interaction events measured are within a suitable level for the device to permit detection and tracking.
- any suitable apparatus may be used.
- Standard iScat apparatus or Interference Reflection Microscopes may be suitable for some embodiments.
- Mass photometers available from Refeyn, UK may be suitable.
- no labelling of the biomolecule is required.
- the biomolecule is not tethered to the surface.
- the present invention involves the use of interferometric light scattering apparatus, such as a microscope or mass photometer. Such devices interrogate the interface between the sample and the surface. Such an apparatus may take a plurality of measurements. The biomolecules on the surface scatter light, producing contrast in the measurement. It is possible to localise each scattering event (and thus each biomolecule) by fitting the contrast signal to a profile (such as a Gaussian profile) and localising that event to the peak of that fit. Repeated measurements may be taken at a suitable rate, depending on the expected speed of the movement of the biomolecule. A suitable rate at which the measurements are taken is the range of 10Hz to 10kHz, optionally 50Hz to 5KHz, preferably 100Hz to 1kHz.
- Any suitable rate may be selected within or from these ranges.
- Individual biomolecules may thus be tracked by using repeated fitting of the contrast signal and repeated localisation, creating a "trajectory" of the biomolecule over the surface. If the contrast signal disappears, this is indicative that the biomolecule has detached from the surface. Measurements that may therefore be taken to indicate mobility include, but are not limited to: time associated with the surface, distance travelled on the surface, speed of movement on the surface and/or frequency of interaction with the surface (measurement of association/dissociation with surface).
- the measurements taken may be used to construct a profile for the biomolecule. For example, normalised counts for distance moved can be plotted, or the speed the biomolecule moves can be plotted. Alternatively, the trajectory of the biomolecule can be plotted (see Figure 3 inset); the trajectory being the path taken by the biomolecule across the surface.
- the constructed profile may therefore reflect various characteristics or properties of the biomolecule, according to their interaction with the surface.
- a reference profile may be prepared by taking a known biomolecule and performing the method as described with at least a first and second surface.
- This reference profile may be single combined profile based on multiple data sets for two or more surfaces, or may be a set of profiles obtained from each surface individually.
- a summary of the interactions (such as the mobility) of a biomolecule with a surface may be used to construct a profile.
- a profile may be defined as a set of characteristics that identify or are thought to identify a particular biomarker.
- the profile may be a summary or analysis of data, in any appropriate form, such as a graph or table, representing distinctive characteristics.
- the reference profile may be stored in a database permitting comparison to take place by computer-implemented means.
- Figures 3 and 4 contain representations of the collected data that may be used to construct a profile for a biomarker.
- the profile constructed using the methods of the invention may be compared to a reference profile.
- This entails examining the biomarker profile and a reference profile to find similarities. Similarities in profile attributes enables identification of the biomolecule.
- the comparison has to be meaningful, such that the same characteristics are determined for both the reference biomarker and the biomarker in the sample. Generally, this will mean that the first and second (and any further) surfaces are the same for both the reference biomarker and the sample biomarker.
- a surface that can be used to determine hydrophobicity could have exposed methyl (- CH 3 ), methylene (- CH 2 -), methoxy (- OCH 3 ), or trifluoromethyl ester (- OCF 3 ) groups, or alternatively comprise or be coated with polymeric biomaterials for example, PTFE, PDMS, PET, polyethylene, and polypropylene.
- a surface may be selected from a class of surfaces designed to investigate a particular property or characteristic of a biomolecule.
- a comparison step may therefore involve comparing an unknown biomarker profile on a "hydrophobic" surface and comparing it to a reference biomarker profile which entailed the use of an alternative "hydrophobic" surface.
- the light used may be: ultraviolet light (which may be defined herein as having wavelengths in the range from lOnm to 380nm); visible light (which may be defined herein as having wavelengths in the range from 380nm to 740nm); infrared light (which may be defined herein as having wavelengths in the range from 740nm to 300pm).
- the light may be a mixture of wavelengths.
- the terms 'optical' and 'optics' are used to refer generally to the light to which the methods are applied.
- Fig. 1 illustrates an iSCAT microscope 1 which is arranged as follows.
- the microscope 1 includes the following components that, except for the spatial filter described in more detail below, have a construction that is conventional in the field of microscopy.
- the microscope 1 comprises a sample holder 2 for holding a sample 3 at a sample location.
- the sample 3 may be a liquid sample comprising objects to be imaged, which are described in more detail below.
- the sample holder 2 may take any form suitable for holding the sample 3.
- the sample holder 2 holds the sample 3 on a surface, which forms an interface between the sample holder 2 and the sample 3.
- the sample holder 2 may be a coverslip and/or may be made from glass.
- the sample 3 may be provided on the sample holder 2 in a straightforward manner, for example using a micropipette.
- the microscope 1 further comprises an illumination source 4 and a detector 5.
- the illumination source 4 is arranged to provide illuminating light.
- the illuminating light may be coherent light.
- the illumination source 4 may be a laser.
- the wavelength of the illuminating light may be selected in dependence on the nature of the sample 3 and/or the properties to be examined. In one example, the illuminating light has a wavelength of 405nm.
- the illumination light may be modulated spatially, to remove speckle patterns that arise from the coherent nature of the illumination and laser noise, for example as detailed in Kukura et al., "High-speed nanoscopic tracking of the position and orientation of a single virus", Nature Methods 20096:923-935.
- the detector 5 receives output light in reflection from the sample location.
- the microscope 1 may operate in a wide-field mode, in which case the detector 5 may be an image sensor that captures an image of the sample 3.
- the microscope 1 may alternatively operate in a confocal mode, in which case the detector 5 may be an image sensor or may be a point-like detector, such as a photo-diode, in which case a scanning arrangement may be used to scan a region of the sample 3 to build up an image.
- image sensors that may be employed as the detector 5 include a CMOS (complementary metal-oxide semiconductor) image sensor or a CCD (charge-coupled device).
- the microscope 1 further comprises an optical system 10 arranged between the sample holder 2, the illumination source 4 and the detector 5.
- the optical system 10 is arranged as follows to direct illuminating light onto the sample location for illuminating the sample 3, and to collect output light in reflection from the sample location and to direct the output light to the detector 5.
- the optical system 10 includes an objective lens 11 which is a lens system disposed in front of the sample holder 2.
- the optical system 10 also includes a condenser lens 12 and a tube lens 13.
- the condenser lens 12 condenses illuminating light from the light source 11 (shown by continuous lines in Fig. 1) through the objective lens 11 onto the sample 3 at the sample location.
- the objective lens 11 collects the output light which comprises both (a) illuminating light reflected from the sample location (shown by continuous lines in Fig. 1), and (b) light scattered from the sample 3 at the sample location (shown by dotted lines in Fig. 1).
- the reflected light is predominantly reflected from the interface between the sample holder 2 and the sample 3.
- this is a relatively weak reflection, for example a glass-water reflection.
- the intensity of the reflected illuminating light may be of the order of 0.5% of the intensity of the incident illuminating light.
- the scattered light is scattered by objects in the sample 3.
- the reflected illuminating light and the scattered light have different directionalities.
- the reflected illuminating light has a numerical aperture resulting from the geometry of the beam of light output by the light source 4 and the optical system 6.
- the scattered light is scattered over a large range of angles and so fills larger numerical aperture than the reflected illuminating light.
- the tube lens 13 focuses the output light from the objective lens 11 onto the detector 5.
- the optical system 6 also includes a beam splitter 14 that is arranged to split the optical paths for the illuminating light from the light source 4 and the output light directed to the detector 5.
- the beam splitter 14 may have a conventional construction that provides partial reflection and partial transmission of light incident thereon.
- the beam splitter 14 may be a plate, typically provided with a film, which may be metallic or dielectric, arranged at 45° to the optical paths.
- the beam splitter 14 may be a cube beam splitter formed by a matched pair of prisms having a partially reflective film at the interface between the prisms.
- the beam splitter 14 may be a polarising beam splitter, used in combination with a quarter wave plate between the beam splitter 14 and the sample 3.
- the light source 4 is offset from the optical path of the objective lens 11 so that the illuminating light from the light source 4 is reflected by the beam splitter 14 into the objective lens 11, and conversely the detector 5 is aligned with the optical path of the objective lens 11 so that the output light from the sample location is transmitted through the beam splitter 14 towards the detector 5.
- the microscope 1 includes a spatial filter 20.
- the spatial filter 20 is formed on the beam splitter 14 and is thereby positioned behind the back aperture of the objective lens 11, and so directly behind the back focal plane 15 of the objective lens 11.
- the spatial filter 20 may be implemented without entering the objective lens as in phase contrast microscopy. Placing the spatial filter directly behind the entrance aperture of the objective rather than in a conjugate plane (for example as described below) has the distinct advantage of strongly suppressing back reflections originating from the numerous lenses within high numerical aperture microscope objectives. This, in turn, reduces imaging noise, lowers non-interferometric background and reduces the experimental complexity, number of optics and optical pathlength leading to increased stability of the optical setup and thus image quality.
- the spatial filter 20 is thereby positioned to filter the output light passing to the detector 5.
- the spatial filter 20 is therefore transmissive.
- the spatial filter 20 is partially transmissive and therefore passes the output light, which includes the reflected illumination light, but with a reduction in intensity.
- the spatial filter 20 is also aligned with the optical axis and has a predetermined aperture so that it provides a reduction in intensity within a predetermined numerical aperture.
- numerical aperture is defined in its normal manner as being a dimensionless quantity characterising a range of angles with respect to the sample location from which the output light originates.
- the spatial filter 20 provides no intensity reduction outside the predetermined numerical aperture.
- the spatial filter 20 could alternatively provide a reduction in intensity outside its predetermined aperture, but a reduction in intensity that is less than the reduction in intensity within the predetermined numerical aperture, although this is less desirable.
- the spatial filter 20 may be formed in any suitable manner, typically comprising a layer of deposited material.
- the material may be, for example, a metal such as silver.
- the deposition may be performed using any suitable technique.
- the reduction in intensity provided by the spatial filter 20 preferentially reduces the intensity in detection of the reflected illuminating light over the scattered light. Accordingly, the reduction in intensity by the spatial filter 20 at low numerical apertures predominantly affects the reflected illuminating light and has a minimal effect on the scattered light, thereby maximising the contrast in the capture image.
- the enhanced imaging contrast enables high contrast detection of objects that are weak scatterers.
- contrast is provided in a similar manner to conventional iSCAT, but controlled additionally by the transmissivity of the spatial filter.
- This provides the ability to tune the amplitude of the reference field directly through selection of the transmissivity t 2 of the spatial filter 20 as opposed to being fixed by the reflectivity of a glass-water interface as in standard iSCAT.
- the transmissivity t 2 may be selected by choice of the material and/or thickness of the layer. Such tuning may be performed according to, for example, the scattering object of interest, the camera full well capacity and magnification.
- the predetermined numerical aperture may be the numerical aperture of the reflected illuminating light within the output light, but that is not essential. For example, benefits of a similar nature could be achieved if the predetermined numerical aperture was slightly smaller than, or larger than the numerical aperture of the reflected illuminating light.
- the spatial filter 20 does not fundamentally alter the sensitivity limits or SNR (signal to noise ratio) achievable for scattering by a given object, incident light intensity and exposure time. However, by improving the contrast and reducing the overall detected photon flux, it does, however, dramatically simplify the implementation of iSCAT to achieve a given sensitivity or SNR.
- Existing iSCAT microscopes have complex and expensive components, for example requiring an optical table, and expensive and complex optics, electronics, as well as needing expert operation. Such requirements are greatly relaxed by the use of the spatial filter 20. Equivalent performance to existing iSCAT microscopes may be achieved, for example, simply by adding the spatial filter 20 to an existing commercial microscope that does not have the complex and expensive components mentioned above.
- the spatial filter 20 itself is of course a simple and cheap component.
- the spatial filter 20 enables use of standard CMOS or CCD cameras with low full well capacity without loss of imaging sensitivity.
- FIG. 2 An image acquired using an example of the microscope 1 is shown in Fig. 2.
- coherent brightfield illuminating light was provided and the spatial filter 20 comprised by a layer of silver of thickness 180 nm deposited on fused silica with a 3.5 mm diameter so as to transmit lxlO -2 of the reflected light intensity.
- Fig. 2 is an image captured using a low cost CMOS camera as the detector 5.
- a high contrast image is achieved.
- brightfield illumination ensures that the strongest unwanted back-reflections, usually originating from the objective are directed away from the detector 5, minimising imaging background and enabling large fields of view without complex scanning of the beam of illuminating light.
- the present invention may be applied with advantage to a sample comprising objects having a mass of 5000 kDa or less.
- the present invention may be applied to a sample comprising objects having a mass of 10 kDa or more, for example objects having a mass within a range from 10 kDa to 5000 kDa.
- the present invention may be applied to a sample comprising objects having a scattering cross section with respect to the illuminating light of 10 12 m 2 or less, or more preferably 10 17 m 2 or less.
- objects may also have a scattering cross section with respect to the illuminating light.
- objects may also have a scattering cross section with respect to the illuminating light of 10 20 m 2 , or more preferably 10 26 m 2 or more, for example within a range from 10 17 m 2 from 10 26 m 2 .
- Scattering cross section is a fundamental, measurable property relating to the effective size of an object to incident light of a particular wavelength, independent of the technique used to measure it. Scattering cross sections can be, for example, measured by dark field microscopy. Examples of objects to which the present invention may be applied include proteins or small aggregates thereof, or their binding partners.
- the spatial filter 20 may be arranged to pass reflected illuminating light with a reduction in intensity within the predetermined numerical aperture to an intensity in the range from 10 2 tol0 4 of the incident intensity (in this context, the intensity of the output light that is incident on the spatial filter 20).
- the microscope 1 may be designed and operated without reference to the spatial filter 20.
- the field of view is adjustable by changing the focusing conditions of the illumination light.
- multi-colour imaging requires no more than coupling additional laser sources into a single mode fibre, if such a fibre is used to deliver the illumination light.
- the microscope 1 may be adapted to use other components and techniques known for iSCAT, for example as disclosed in Kukura et al., "High-speed nanoscopic tracking of the position and orientation of a single virus", Nature Methods 20096:923-935, and in Ortega-Arroyo et al. "Interferometric scattering microscopy (iSCAT): new frontiers in ultrafast and ultrasensitive optical microscopy", Physical Chemistry Chemical Physics 2012 14:15625-15636.
- a sample suspected or known to comprise a biomolecule is placed on a sample holder with a glass surface.
- the microscope 1 takes a plurality of measurements of the particles in the sample at the surface at a rate of 100 Hz to 1 kHz.
- Individual particles contacting the surface scatter the measurement light, producing contrast in the measurement.
- Each scattering event is localised by fitting the contrast signature to a profile (e.g. a Gaussian profile) and localizing the event to the peak of that fit.
- Individual particles are tracked using repeated fitting of the contrast signal and repeated localisation creating trajectories of each particle over the surface. This enables the "lateral" mobility to be monitored and thus measured.
- the distance each biomolecule moves during its interaction with the surface can be calculated, or the length of time the biomolecule interacts with the surface can be measures to determine the mobility, and the molecular mass of each biomolecule may be calculated. Normalised counts for the distance moved can be plotted, as shown in Figure 3. How far a biomolecule moves during interaction with the surface indicates the strength of interaction with the surface and can therefore indicate different characteristics about the biomolecule. How often the biomolecule moves away from the surface and/or how long the biomolecule interacts with the surface also indicates the strength of the interaction with the surface and can indicate different characteristics about the biomolecule.
- AAVs biomolecules - Adeno-Associated Viruses
- AAV9 Adeno-Associated Viruses
- AAV5 and AAV9 have different mobilities on the surface, with AAV9 having a more pronounced range of mobility between 0-10nm range.
- Different AAV serotypes have variations on the surface of their capsids that may be involved in receptor binding, host tropism, and antigenic determinants.
- the method can make a determination between AAV5 and AAV9 based on their different capsid chemistries, since this alters their mobility on the surface.
- this data can be used to construct a reference profile for AAV5 and/or AAV9 which can be used to determine the serotype of an unknown AAV sample by constructing a profile using the methods of the invention for the unknown sample.
- the surface of the sample holder and/or the coating on the surface of the sample holder can be chosen to determine specific characteristics of the biomolecule, either the characteristics of the external surface of the biomolecule, or internal characteristics can be determined, i.e. by exposing a protein to a hydrophobic surface which can cause unfolding, or by adding a denaturant to the sample to purposively unfold the biomolecule.
- the method described above uses the distance moved as indicative of the mobility.
- a sample comprising an immunoglobulin IgG is placed on a sample holder comprising a surface, which is either glass or a glass surface coated with TMCS (trimethylchlorosilane modified surface) and the mobility is measured (as for the first method).
- the microscope 1 takes a plurality of measurements of the particles in the sample at the surface at a rate of 100 Hz to 1 kHz. From these measurements, the distance each biomolecule moves during its interaction with the surface can be calculated to determine the mobility, and the molecular mass of each biomolecule may be calculated. Normalised counts for the distance moved can be plotted, as shown in Figure 4a and 4b.
- Frequency, speed and distance of biomolecule movement during interaction with the surface indicate the strength of interaction with the surface and can therefore indicate different characteristics about the biomolecule. How often the biomolecule moves away from the surface and/or how long the biomolecule interacts with the surface also indicates the strength of the interaction with the surface and can indicate different characteristics about the biomolecule. Either or both measurements note the mobility of the molecule.
- Immunoglobulin G (IgG) antibodies are large globular proteins with a molecular weight of about 150 kDa composed of two different kinds of polypeptide chain. One, of approximately 50 kDa, is termed the heavy chain, and the other, of 25 kDa, is termed the light chain.
- Each IgG molecule consists of two heavy chains and two light chains. The two heavy chains are linked to each other by disulphide bonds and each heavy chain is linked to a light chain by a disulphide bond. IgG may further be glycosylated.
- Figure 5 illustrates a typical IgG molecule, with two heavy (dotted bars) and two light (striped bars) chains.
- Each chain has carboxyl (-COOH) and amine (-NH2) groups, provided by terminal and internal amino acids.
- the heavy chains are linked with two disulphide bridges in the hinge region.
- Each light chain is linked to its respective heavy chain through a disulphide bridge.
- Amine and carboxyl groups are the reactive functional groups present in the physiological state.
- Sulfhydryl groups can be generated after reducing the disulphide bonds (such as by changing the conditions to include reducing reagents including DTT or TCEP).
- Carbohydrates can be activated by periodate treatment (oxidising agent). A net negative charge will be attained at a pH higher than its pi, which may be achieved using a buffer. Immunoglobulins may then be less mobile on positively charged surfaces since they are "immobilised” by ionic/ electrostatic interactions.
- Silanes are silicon chemicals possessing a hydrolytically sensitive centre that can react with inorganic substrates (such as glass) to form stable covalent bonds and that possess an organic substitution which alters the physical interactions of treated substrates.
- Some of the properties of the surface that can be modified with silanes include: hydrophobicity, adhesion, release, dielectric, absorption, orientation, hydrophilicity, and/or charge conduction.
- Silane treatments of surfaces involve a liquid phase or vapour phase chemical reaction, and are straightforward to perform and of low cost. Silane reactions are most often used to modify hydroxylated surfaces. Since glass is rich in hydroxyl groups, silanes are particularly useful for modifying this material. Numerous silane compounds are commercially available, permitting a broad range of chemical functionalities to be incorporated on surfaces. The advantages of silane reactions are their simplicity and stability, attributed to their covalent, cross-linked structure.
- the IgG molecule is relatively mobile on glass, with some IgG molecules moving as far as 400nm whilst being monitored.
- the amount of mobility is greatly restricted. This represents a different type of interaction between the IgG molecule and the surface.
- the IgG on the modified surface may form covalent bonds, which restricts mobility on the surface, and furthermore restricts the immunoglobulins from leaving the surface; or it is possible that the IgG has partially unfolded, restricting mobility.
- the mobility of this IgG on glass and a modified surface may be used to construct a reference profile for the IgG which can be used as a comparison when data on an unknown immunoglobulin is obtained.
- Example 1 The invention will now be described with reference to several specific Examples, which are not limiting to the scope of the invention: Example 1
- Adeno-associated viruses are non-pathogenic viruses composed of a protein shell surrounding and protecting a small, single-stranded DNA genome.
- the expected molecular weight (MW) of empty AAV capsids is about 3700 kDa.
- MW molecular weight
- a sample of known AAV5 or AAV9 was diluted to a final concentration of approximately lxlO 11 pp/ml or lxlO 11 vg/ml.
- the aim is to have 500 to 2000 events in the AAV mass range using the mass photometer.
- the sample was placed on a sample holder with a glass slide (in this instance a non- functionalised surface with mixed natural charge).
- the mass photometer takes a plurality of measurements of the AAV in the sample at the surface at a rate of 100 Hz to 1 kHz, generally 1 kHz.
- Individual AAV particles contacting the surface scatter the measurement light, producing contrast in the measurement.
- Each scattering event is localised by fitting the contrast signature to a profile (e.g.
- each AAV particle is tracked using repeated fitting of the contrast signal and repeated localisation creating trajectories of each AAV particle over the surface. This enables the "lateral" mobility to be monitored and thus measured. However, if the contrast signal disappears, the particle has detached from the surface, and this is indicative of mobility on/off the surface (indicating particular characteristics in terms of interaction with the surface). From these measurements the distance each AAV particle moves during its interaction with the surface can be calculated, or the length of time the AAV particle interacts with the surface can be measured to determine the mobility, and the molecular mass of each AAV particle may be calculated.
- a sample of IgG (Sigma Aldrich, UK) was diluted such that 500 to 2000 events in the IgG mass range using the mass photometer was achievable and placed in a sample holder including either a glass surface or a sample holder including a surface derivatised with trimethylchlorosilane (Gelest, US).
- the mass photometer takes a plurality of measurements of the IgG in the sample at the surface at a rate of 100 Hz to 1 kHz. From these measurements, the distance each IgG molecule moves during its interaction with the surface was calculated to determine the mobility, along with the molecular mass (data not shown). Normalised counts for the distance moved was plotted, as shown in Figures 4a and 4b.
- IgG has a substantially reduced mobility on the derivatised surface in comparison to glass, in line with a different mechanism of interaction with the derivatised surface.
- the mobilities of the IgG on the class and derivatised surfaces may be used to construct a reference profile for this IgG molecule.
- Such reference profile serves as a comparator for profiles from other immunoglobulins to determine the identity of the unknown immunoglobulin.
- a method of identifying a biomolecule in a sample comprising contacting said sample with a first surface and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the first surface to determine at least one physical characteristic of said biomolecule.
- a method as claimed in clause A further comprising contacting said sample with a second surface and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the second surface to determine at least one physical characteristic of said biomolecule.
- a method of identifying a biomolecule in a sample according to clause A comprising: contacting said sample with a first surface, and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the first surface, contacting said sample with a second surface, and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the second surface, and combining or comparing the measurements on the first and second surfaces to determine the identity of the biomolecule.
- a method of identifying a biomolecule in a sample comprising: contacting said sample with a first surface under a first set of conditions, and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the first surface under the first conditions, contacting said sample with a first surface under a second set of conditions, and using an interferometric scattering apparatus to take a plurality of measurements of said biomolecule over time, and using the plurality of measurements to determine the mass and mobility of the biomolecule on the first surface under the second conditions, and combining or comparing the measurements under the first and second conditions to determine the identity of the biomolecule.
- the surface is selected from any one of the following: glass, diamond, plastic, polymeric material (e.g. cyclic olefin copolymer, polyvinyl, polyethylene (PE) including for example polyethylene terephthalate (PET) and high-density polyethylene (HDPE) and low-density polyethylene (LDPE), polyacrylate (acrylic), polystyrene (PS) including high impact polystyrene (HIPS), silicone, polyester (for example polylactic acid (PLA) or polylactic coglycolic acid (PGLA)), polyurethane, polypropylene (PP), polyamide (nylon), Acrylonitrile butadiene styrene (ABS), Polyethylene/Acrylonitrile Butadiene Styrene (PE/ABS), bakelite, rubber, latex, polycarbonate (PC), Polycarbonate/Acrylonitrile Butadiene Styrene (PC/ABS) and polyvinyl, polyethylene (PE) including for example
- a method according to any one of the preceding clauses wherein using the plurality of measurements to determine the mobility of the biomolecule comprises determining any one or more of: how long surface interactions between the biomolecule in the sample and the surface last, how far the species in the sample move along the surface during the surface interaction or a combination thereof.
- a method for release testing a biological molecule during manufacture comprising the use of a method as defined in any one of clauses A to M.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Signal Processing (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Computing Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280049837.8A CN117716225A (zh) | 2021-07-16 | 2022-07-18 | 确定生物分子身份的方法 |
JP2024502025A JP2024529886A (ja) | 2021-07-16 | 2022-07-18 | 生体分子の同一性を決定する方法 |
EP22743881.9A EP4370899A1 (de) | 2021-07-16 | 2022-07-18 | Verfahren zur bestimmung der identität eines biomoleküls |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2110264.5A GB202110264D0 (en) | 2021-07-16 | 2021-07-16 | Method |
GB2110264.5 | 2021-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023285842A1 true WO2023285842A1 (en) | 2023-01-19 |
Family
ID=77443512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2022/051853 WO2023285842A1 (en) | 2021-07-16 | 2022-07-18 | Method of determining the identity of a biomolecule |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4370899A1 (de) |
JP (1) | JP2024529886A (de) |
CN (1) | CN117716225A (de) |
GB (1) | GB202110264D0 (de) |
WO (1) | WO2023285842A1 (de) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180275097A1 (en) * | 2015-09-07 | 2018-09-27 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E. V. | Method and apparatus for detecting particles, like biological macromolecules or nanoparticles |
US20200096472A1 (en) * | 2018-09-26 | 2020-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Optical imaging of single molecule size, charge, mobility, binding and conformational change |
WO2020104814A2 (en) * | 2018-11-22 | 2020-05-28 | Cambridge Enterprise Limited | Particle characterization using optical microscopy |
-
2021
- 2021-07-16 GB GBGB2110264.5A patent/GB202110264D0/en not_active Ceased
-
2022
- 2022-07-18 WO PCT/GB2022/051853 patent/WO2023285842A1/en active Application Filing
- 2022-07-18 JP JP2024502025A patent/JP2024529886A/ja active Pending
- 2022-07-18 EP EP22743881.9A patent/EP4370899A1/de active Pending
- 2022-07-18 CN CN202280049837.8A patent/CN117716225A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180275097A1 (en) * | 2015-09-07 | 2018-09-27 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E. V. | Method and apparatus for detecting particles, like biological macromolecules or nanoparticles |
US20200096472A1 (en) * | 2018-09-26 | 2020-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Optical imaging of single molecule size, charge, mobility, binding and conformational change |
WO2020104814A2 (en) * | 2018-11-22 | 2020-05-28 | Cambridge Enterprise Limited | Particle characterization using optical microscopy |
Non-Patent Citations (11)
Title |
---|
FOLEY, E.D.B. ET AL.: "Mass photometry enables label-free tracking and mass measurement of single proteins on lipid bilayers", NAT METHODS, vol. 18, 2021, pages 1247 - 1252, XP037580320, DOI: 10.1038/s41592-021-01261-w |
GAUGHAN, C.L., MOLECULAR DIVERSITY, vol. 20, 2016, pages 255 - 270 |
GOLDFAIN AARON M ET AL: "Dynamic Measurements of the Position, Orientation, and DNA Content of Individual Unlabeled Bacteriophages", JOURNAL OF PHYSICAL CEMISTRY, 11 April 2016 (2016-04-11), XP055904881, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/27063451> [retrieved on 20220324] * |
KUKURA ET AL.: "High-speed nanoscopic tracking of the position and orientation of a single virus", NATURE METHODS, vol. 6, 2009, pages 923 - 935 |
ORTEGA-ARROYO ET AL.: "Interferometric scattering microscopy (iSCAT): new frontiers in ultrafast and ultrasensitive optical microscopy", PHYSICAL CHEMISTRY CHEMICAL PHYSICS, vol. 14, 2012, pages 15625 - 15636 |
RAMANAN, BIODRUGS, vol. 28, 2014, pages 363 - 372 |
STRACK, R.: "Weighing single proteins with light", NAT METHODS, vol. 15, 2018, pages 477, XP036538852, DOI: 10.1038/s41592-018-0055-6 |
VALA, M.PILIARIK, M.: "Weighing single protein complexes on the go", NAT METHODS, vol. 18, 2021, pages 1159 - 1160, XP037580318, DOI: 10.1038/s41592-021-01263-8 |
YOUNG ET AL., SCIENCE, vol. 360, 27 April 2018 (2018-04-27), pages 423 - 427 |
YOUNG ET AL., SCIENCE, vol. 360, no. 6387, 2018, pages 423 - 7 |
YOUNGKUKURA, ANNUAL REVIEW OF PHYSICAL CHEMISTRY, vol. 70, no. 1, 2019, pages 301 - 322 |
Also Published As
Publication number | Publication date |
---|---|
EP4370899A1 (de) | 2024-05-22 |
JP2024529886A (ja) | 2024-08-14 |
CN117716225A (zh) | 2024-03-15 |
GB202110264D0 (en) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Arima et al. | Identifying single viruses using biorecognition solid-state nanopores | |
EP2306176B1 (de) | Chip für optische Analyse | |
US9829434B2 (en) | Optical detection system for liquid samples | |
Obeid et al. | Development of a NanoBioAnalytical platform for" on-chip" qualification and quantification of platelet-derived microparticles | |
WO2020160472A1 (en) | High-sensitivity assay | |
EP2287609B1 (de) | Verfahren zur herstellung eines unlöslichen trägerpartikels, unlösliches trägerpartikels, messreagens, probenanalysewerkzeug und immunologisches turbidimetrieverfahren | |
JP2013533469A (ja) | 免疫診断における生物学的および化学的分析および用途における粒子の位置的自由度の検出のための方法および装置 | |
US11635431B2 (en) | Apparatus for analyzing and detecting interactions and reactions of molecules | |
JP7254349B2 (ja) | 生体分子標的の光検知システム及び方法 | |
Choi et al. | Label-free detection of glycoproteins using reflectometric interference spectroscopy-based sensing system with upright episcopic illumination | |
CN104053992B (zh) | 确定包括细胞的体液中的靶分子的存在 | |
US20240319091A1 (en) | Method of determining the identity of a biomolecule | |
Wan et al. | Single-protein identification by simultaneous size and charge imaging using evanescent scattering microscopy | |
WO2023285842A1 (en) | Method of determining the identity of a biomolecule | |
JP2020523554A (ja) | 試料中におけるバイオ治療物質凝集体の検出方法 | |
Jiang et al. | Label-free probing of molecule binding kinetics using single-particle interferometric imaging | |
Borgos et al. | Characterization methods: Physical and chemical characterization techniques | |
Zourob et al. | Label-free detection with the resonant mirror biosensor | |
JP4660431B2 (ja) | 生体物質検出・回収方法およびその装置及び生体物質解析方法 | |
RU2437937C1 (ru) | СПОСОБ ОПРЕДЕЛЕНИЯ НАЛИЧИЯ БАКТЕРИЙ Escherichia coli ПО ДЕТЕКТИРОВАНИЮ ИХ ФРАГМЕНТОВ С ПОМОЩЬЮ АТОМНО-СИЛОВОЙ МИКРОСКОПИИ | |
WO2023178704A1 (zh) | 一种多肽探针及其制备方法与应用 | |
JP2023504603A (ja) | 凝集体の決定方法 | |
US20240044787A1 (en) | Coronavirus mutation determination device comprising metamaterial array and electromagnetic wave irradiation unit | |
Nazarian | Improved Single-Molecule Detection of Native Proteins Using Hydrogel-Backed Nanopores | |
WO2013146249A1 (ja) | 等電点の測定方法、ならびにそのためのセンサーチップ、測定装置、測定システムおよびプログラム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22743881 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2024502025 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280049837.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022743881 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022743881 Country of ref document: EP Effective date: 20240216 |